Jump to:

Patient Resources

Display:
A - Z All Fact Sheets
Travel Fact Sheets

Systemic Lupus Erythematosus (SLE)

What is systemic lupus erythematosus ?

Systemic lupus erythematosus is often referred to as SLE or just Lupus. Lupus comes from the Latin name for wolf and was originally used as a descriptive term because of the erosion of the skin which looked as though it had been gnawed.

SLE is a chronic (long-lasting) disease of the immune system in which the body produces too many antibodies. These antibodies circulate in the bloodstream causing inflammation in the joints, muscles and other organs. 

SLE usually affects women of child-bearing age and over 90 per cent of sufferers are female. However, men and children may also develop the disease. It is also more common in black and Asian women than in white women.

Lupus may be classified into three types:

  • Discoid LE (DLE) which tends to remain only as a skin rash and rarely progresses to the more severe form of SLE
  • Drug-Induced SLE which may cause different symptoms to develop
  • SLE which is the most chronic form of the disease

What are the symptoms of SLE?

SLE can vary in severity from a mild form of the disease affecting only a few organs of the body to a much more serious form that can cause severe symptoms and may be life-threatening.

A red rash usually occurs on the face which is often exacerbated by sunlight. This often has a characteristic "butterfly" distribution over the cheeks. SLE can affect almost every organ and generally causes a mild form of arthritis that can affect one or more joints. Many sufferers experience severe fatigue and weakness. Hair loss, mouth ulcers, poor circulation in the fingers (Raynaud's syndrome) and headaches are also commonly found in people with this disease. In severe forms of the disease, damage to the heart, kidney, lungs and brain may occur. These severe effects do not occur in drug-induced SLE.

The disease progresses differently in each person affected, so it is difficult to predict the course that the disease will take. Some people may never develop serious complications, but for those that do treatment is improving.

The disease is characterised by episodes of illness and periods of improvement or remission. Remission may last for weeks, months or even years.

What is the cause of SLE?

The exact cause of SLE is still unknown but it is thought that the environment, hormonal changes and hereditary factors may all be involved.

An antinuclear antibody (ANA) is usually found in the blood of a person with SLE. This can be an important test for diagnosing the disease. A blood test will also show a low white blood cell count and anaemia.

Drug-induced SLE may be caused by a wide variety of drugs but the symptoms will subside when the drug that is causing them is stopped.

What treatment is available?

The mainstay of treatment for SLE is corticosteroids. The corticosteroid prescribed most commonly is prednisolone; methylprednisolone injection may be prescribed for acute attacks.

Medication is usually prescribed individually for each person according to the type and severity of symptoms. For example, an antimalarial drug such as chloroquine (eg, Nivaquine®) or hydroxychloroquine (Plaquenil®) may be given to treat symptoms such as photosensitivity, inflammatory rashes or arthralgia. Aspirin or a non-steroidal anti-inflammatory drug (eg, ibuprofen) may be given to treat mild arthralgia. They may be given together with corticosteroids.

Immunosuppressant drugs such as azathioprine, methotrexate or cyclophosphamide may also be prescribed.

Further information available from:

Lupus UK
St James House
Eastern Road
Romford
Essex RM1 3NH
Tel: 01708 731251
Email: headoffice@lupusuk.org.uk
Internet: www.lupusuk.com

Fact sheet provided by MIMS

Date last reviewed: February 2008 

 

Latest Guidelines

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Technology Appraisal Guidance No. 192 Source: National Institute for Health and...

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

Technology Appraisal Guidance No. 193 Source: National Institute for Health and...

Capecitabine for the treatment of advanced gastric cancer

Technology Appraisal Guidance No. 191 Source: National Institute for Health and...

Pemetrexed for the maintenance treatment of non-small-cell lung cancer

Technology Appraisal Guidance No. 190 Source: National Institute for Health and...

Human growth hormone (somatropin) in children with growth failure

Technology Appraisal Guidance No. 188 Source: National Institute for Health and...

 

GP Curriculum Centre

Educational resource for the learning and teaching of the
GP curriculum

Click here to read more

Deleted products

Cumulative list of products discontinued from the UK market
in 2010

Click here to read more

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Find drugs by:

NICE Guidance: IBS

NICE Guidance: IBS

MIMS Summary of
NICE guideline

NICE Guidance: Lipid Modification

NICE Lipid Modification

MIMS Summary of
NICE guideline

Quick-reference table: antibiotics

Antibiotics Table

Treatment regimens for common infections

Referral Guidelines for Breast Disorders

NHS Cancer Screening

MIMS Summary of NHS Cancer Screening Referral Guidelines

 

Back to top